Alphamab Oncology (HKSE:09966) Change In Payables And Accrued Expense : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Change In Payables And Accrued Expense?

Alphamab Oncology's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was HK$0.0 Mil. It means Alphamab Oncology's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Alphamab Oncology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was HK$0.0 Mil. It means Alphamab Oncology's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Alphamab Oncology Change In Payables And Accrued Expense Historical Data

The historical data trend for Alphamab Oncology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Change In Payables And Accrued Expense Chart

Alphamab Oncology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Alphamab Oncology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial								-	-	-	-	-

Alphamab Oncology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Alphamab Oncology Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

3NK:Germany

Address

No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024

Website

https://www.alphamabonc.com

Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines